BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18979097)

  • 1. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody.
    Wang W; Nishioka Y; Ozaki S; Jalili A; Abe S; Kakiuchi S; Kishuku M; Minakuchi K; Matsumoto T; Sone S
    Cancer Immunol Immunother; 2009 Jun; 58(6):967-76. PubMed ID: 18979097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
    Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
    Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models.
    Kawai S; Azuma Y; Fujii E; Furugaki K; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
    Cancer Sci; 2008 Dec; 99(12):2461-6. PubMed ID: 19032371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24.
    Ozaki S; Kosaka M; Wakatsuki S; Abe M; Koishihara Y; Matsumoto T
    Blood; 1997 Oct; 90(8):3179-86. PubMed ID: 9376601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells.
    Ozaki S; Kosaka M; Wakahara Y; Ozaki Y; Tsuchiya M; Koishihara Y; Goto T; Matsumoto T
    Blood; 1999 Jun; 93(11):3922-30. PubMed ID: 10339501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity.
    Ono K; Ohtomo T; Yoshida K; Yoshimura Y; Kawai S; Koishihara Y; Ozaki S; Kosaka M; Tsuchiya M
    Mol Immunol; 1999 Apr; 36(6):387-95. PubMed ID: 10444002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-ganglioside GM2 monoclonal antibody-dependent killing of human lung cancer cells by lymphocytes and monocytes.
    Hanibuchi M; Yano S; Nishioka Y; Yanagawa H; Sone S
    Jpn J Cancer Res; 1996 May; 87(5):497-504. PubMed ID: 8641987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
    Tai YT; Horton HM; Kong SY; Pong E; Chen H; Cemerski S; Bernett MJ; Nguyen DH; Karki S; Chu SY; Lazar GA; Munshi NC; Desjarlais JR; Anderson KC; Muchhal US
    Blood; 2012 Mar; 119(9):2074-82. PubMed ID: 22246035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models.
    Kawai S; Yoshimura Y; Iida S; Kinoshita Y; Koishihara Y; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
    Oncol Rep; 2006 Feb; 15(2):361-7. PubMed ID: 16391855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells.
    Ohtomo T; Sugamata Y; Ozaki Y; Ono K; Yoshimura Y; Kawai S; Koishihara Y; Ozaki S; Kosaka M; Hirano T; Tsuchiya M
    Biochem Biophys Res Commun; 1999 May; 258(3):583-91. PubMed ID: 10329429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of a conventional non-radioisotope method to quantify HM1.24 antigens: correlation of HM1.24 levels and ADCC activity of the humanized antibody against HM1.24.
    Kawai S; Koishihara Y; Iida S; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
    Leuk Res; 2006 Aug; 30(8):949-56. PubMed ID: 16473407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors.
    Harada T; Ozaki S; Oda A; Tsuji D; Ikegame A; Iwasa M; Udaka K; Fujii S; Nakamura S; Miki H; Kagawa K; Kuroda Y; Kawai S; Itoh K; Yamada-Okabe H; Matsumoto T; Abe M
    PLoS One; 2013; 8(12):e83905. PubMed ID: 24386306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunodetection of human myeloma xenografts with a monoclonal antibody directed against a plasma cell specific antigen, HM1.24.
    Ozaki S; Kosaka M; Harada M; Nishitani H; Odomi M; Matsumoto T
    Cancer; 1998 Jun; 82(11):2184-90. PubMed ID: 9610698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients.
    Ishiguro T; Kawai S; Habu K; Sugimoto M; Shiraiwa H; Iijima S; Ozaki S; Matsumoto T; Yamada-Okabe H
    Cancer Sci; 2010 Oct; 101(10):2227-33. PubMed ID: 20701608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
    Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effect of antibody against a SEREX-defined antigen (UOEH-LC-1) on lung cancer xenotransplanted into severe combined immunodeficiency mice.
    Mizukami M; Hanagiri T; Yasuda M; Kuroda K; Shigematsu Y; Baba T; Fukuyama T; Nagata Y; So T; Ichiki Y; Sugaya M; So T; Takenoyama M; Sugio K; Yasumoto K
    Cancer Res; 2007 Sep; 67(17):8351-7. PubMed ID: 17804751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.
    Staudinger M; Glorius P; Burger R; Kellner C; Klausz K; Günther A; Repp R; Klapper W; Gramatzki M; Peipp M
    Blood Cancer J; 2014 Jun; 4(6):e219. PubMed ID: 24927408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
    Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
    Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
    Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
    Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity.
    Azuma A; Yagita H; Matsuda H; Okumura K; Niitani H
    Cancer Res; 1992 Sep; 52(18):4890-4. PubMed ID: 1381273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.